AZ10397767 is a selective CXCR2 receptor antagonist with oral activity, used to inhibit oxaliplatin-induced NF-κB transcriptional activity, enhance oxaliplatin-induced apoptosis in androgen-independent prostate cancer (AIPC) cells, and significantly suppress neutrophil recruitment to tumors, thereby exerting adverse effects on tumor growth in vitro and in vivo.